A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit (NCT06805825)
A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
🩺 Plain-English Summary (8th-Grade Level)
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Who can join: Review the eligibility criteria below.
Location: University of Michigan Hospitals — Ann Arbor, Michigan
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University of Michigan Hospitals — Ann Arbor, Michigan
- Case Comprehensive Cancer Center — Cleveland, Ohio
- Oregon Health & Science University — Portland, Oregon
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- NEXT Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (617) 870-7173
Email: NN3201@noveltynobility.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Stromal Tumors
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST — Miami, Florida
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Scottsdale, Arizona
- Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. — Houston, Texas
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST — Miami, Florida
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor — La Jolla, California
- Imatinib TDM in GIST — Lexington, Kentucky
Explore by condition: All Gastrointestinal Stromal Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.